Evidence map›Paper›PMID 35579329›Full record

ArticleGlia2022

A unique cerebellar pattern of microglia activation in a mouse model of encephalopathy of prematurity.

Luisa Klein, Juliette Van Steenwinckel, Bobbi Fleiss, Till Scheuer, Christoph Bührer, Valerie Faivre, Sophie Lemoine, Corinne Blugeon, Leslie Schwendimann, Zsolt Csaba and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Glia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Cerebellar Development and the Burden of Prematurity.Cerebellum (London, England) · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Preterm birth: A neuroinflammatory origin for metabolic diseases?Brain, behavior, & immunity - health · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Cerebellar development after preterm birth.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 5 countries.

Luisa KleinDepartment of Neonatology, Charité University Medicine Berlin, Berlin, Germany.
Juliette Van SteenwinckelNeuroDiderot, Inserm, Université de Paris, Paris, France.ORCID 0000-0003-3463-4856
Bobbi FleissNeuroDiderot, Inserm, Université de Paris, Paris, France.
Till ScheuerDepartment of Neonatology, Charité University Medicine Berlin, Berlin, Germany.
Christoph BührerDepartment of Neonatology, Charité University Medicine Berlin, Berlin, Germany.
Valerie FaivreNeuroDiderot, Inserm, Université de Paris, Paris, France.
Sophie LemoineGenomics Core Facility, Département de Biologie, École Normale Supérieure, Institut de Biologie de l'ENS (IBENS), CNRS, INSERM, Université PSL, Paris, France.
Corinne BlugeonGenomics Core Facility, Département de Biologie, École Normale Supérieure, Institut de Biologie de l'ENS (IBENS), CNRS, INSERM, Université PSL, Paris, France.
Leslie SchwendimannNeuroDiderot, Inserm, Université de Paris, Paris, France.
Zsolt CsabaNeuroDiderot, Inserm, Université de Paris, Paris, France.
Cindy BokobzaNeuroDiderot, Inserm, Université de Paris, Paris, France.ORCID 0000-0003-0992-4317
Dulcie A VousdenMouse Imaging Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Jason P LerchMouse Imaging Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Anthony C VernonDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0001-7305-1069
Pierre GressensNeuroDiderot, Inserm, Université de Paris, Paris, France.ORCID 0000-0002-0909-4221
Thomas SchmitzDepartment of Neonatology, Charité University Medicine Berlin, Berlin, Germany.ORCID 0000-0001-8193-8970
Inserm · FRCharité - Universitätsmedizin Berlin · DECentre National de la Recherche Scientifique · FRHospital for Sick Children · CAKing's College London · GBUniversity of Toronto · CA

Funding

Medical Research Council MR/N025377/1Medical Research Council MR/N026063/1Medical Research Council MR/W006251/1
6 · The paper itself

Abstract

Preterm infants often show pathologies of the cerebellum, which are associated with impaired motor performance, lower IQ and poor language skills at school ages. Using a mouse model of inflammation-induced encephalopathy of prematurity driven by systemic administration of pro-inflammatory IL-1β, we sought to uncover causes of cerebellar damage. In this model, IL-1β is administered between postnatal day (P) 1 to day 5, a timing equivalent to the last trimester for brain development in humans. Structural MRI analysis revealed that systemic IL-1β treatment induced specific reductions in gray and white matter volumes of the mouse cerebellar lobules I and II (5% false discovery rate [FDR]) from P15 onwards. Preceding these MRI-detectable cerebellar volume changes, we observed damage to oligodendroglia, with reduced proliferation of OLIG2+ cells at P10 and reduced levels of the myelin proteins myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) at P10 and P15. Increased density of IBA1+ cerebellar microglia were observed both at P5 and P45, with evidence for increased microglial proliferation at P5 and P10. Comparison of the transcriptome of microglia isolated from P5 cerebellums and cerebrums revealed significant enrichment of pro-inflammatory markers in microglia from both regions, but cerebellar microglia displayed a unique type I interferon signaling dysregulation. Collectively, these data suggest that perinatal inflammation driven by systemic IL-1β leads to specific cerebellar volume deficits, which likely reflect oligodendrocyte pathology downstream of microglial activation. Further studies are now required to confirm the potential of protective strategies aimed at preventing sustained type I interferon signaling driven by cerebellar microglia as an important therapeutic target.

Indexed as

Cerebellar DiseasesInfant, Premature, DiseasesInflammationInterferon Type IInterleukin-1betaMicrogliaAnimalsBrain DiseasesCerebellumDisease Models, AnimalFemaleHumansInfant, NewbornInfant, PrematurePregnancyInterferon Type IInterleukin-1betaencephalopathy of prematurityneuroinflammationtertiary phase

Identifiers

PMID35579329
PMCPMC9545095
OpenAlexW4280599137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.